Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome.
Khaled Abd Elaziz Ahmed ElnaghiHosam Ali AlghanmiShereef Ahmed ElsamanyFathia AlmarzokiMohamed ElsaftyMohammad JaffalPublished in: The breast journal (2023)
No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores.